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We studied a strain of exon replacement mice (“L9S knock-in”) whose4 nicotinic receptor subunits have a leucine to serine mutation
in the M2 region, 9 position (Labarca et al., 2001); this mutation renders 4-containing receptors hypersensitive to agonists. Nicotine
induced seizures at concentrations (1 mg/kg) approximately eight times lower in L9S than in wild-type (WT) littermates. At these
concentrations, L9S but not WT showed increases in EEG amplitude and theta rhythm. L9S mice also showed higher seizure sensitivity
to the nicotinic agonist epibatidine, but not to the GABAA receptor blocker and proconvulsant bicuculline. Dorsiflexion of the tail (Straub
tail) was the most sensitive nicotine effect found in L9S mice (0.1 mg/kg). The L9S mice were hypersensitive to galanthamine- and
tacrine-induced seizures and Straub tails. There were no apparent neuroanatomical differences between L9S and WT mice in several
brain regions. [ 125I]Epibatidine binding to brain membranes showed that the mutant allele was expressed at 25% of WT levels,
presumably because of the presence of a neomycin selection cassette in a nearby intron. 86Rb efflux experiments on brain synaptosomes
showed an increased fraction of function at low agonist concentrations in L9S mice. These data support the possible involvement of
gain-of-function 4 receptors in autosomal dominant nocturnal frontal-lobe epilepsy.
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Introduction
Nicotine, the addictive component of tobacco, elicits a wide
range of behavioral effects when administered to rodents (Brioni
et al., 1997). Increasing doses of nicotine in mice can cause seda-
tion, decrease nociception, alter memory and learning, decrease
body temperature, and at high concentrations, induce clonic–
tonic seizures and death. It is not known what roles the various
individual nicotinic receptor types expressed in the mammalian
CNS play in the different nicotine-induced responses. In terms of
its sensitivity to agonist, abundance, and widespread distribution
in the brain, perhaps the most important nicotinic receptor sub-
type is the one formed by 4 coassembled with 2 subunits.
Expression in heterologous systems has shown that 42 recep-
tors have higher sensitivity to nicotine than 7, 22, 32,
34, or 425 receptors (Wonnacott, 1997). 4 and 2 nic-
otinic subunits are abundantly found in the neocortex, hip-
pocampus, septum, thalamus, midbrain, and brainstem (Wada et
al., 1989).
To further understand the function of 4-containing nico-
tinic receptors in the brain, we have created a knock-in mouse
line expressing a hypersensitive 4-containing receptor. Selec-
tion and design of the 4 leucine to serine mutation in the M2
pore lining region at position 9 (L9S) was based on previous
heterologous expression studies: when this conserved leucine was
mutated to serine, there were major increases in agonist sensitiv-
ity (Revah et al., 1991; Labarca et al., 1995). Homozygous L9S
animals containing a neomycin-selection cassette (“neo-intact”)
and heterozygous L9S animals without the cassette (“neo-
deleted”) die soon after birth. However, neo-intact heterozygous
L9S mice have reduced expression of the hypersensitive recep-
tor, are fertile, and display increased anxiety (Labarca et al., 2001)
(these gene dose effects are discussed in Fig. 8, below). We report
now on the effect of this gain-of-function mutation in L9S mice
on seizure and Straub tail responses.
Seizure studies on 4-mutated mice are particularly relevant
for epilepsy research, because all known mutations responsible
for autosomal dominant nocturnal frontal lobe epilepsy (AD-
NFLE) occur in the M2 region of 4 or 2 subunits (for review,
see Sutor and Zolles, 2001). ADNFLE is a rare form of epilepsy
that consists of frequent, brief, and sometimes violent seizures,
starting during childhood, originating in frontal cortex and oc-
curring during sleep. Thus far, and based only on heterologous
expression experiments, there is disagreement as to whether
ADNFLE mutations result in gain or loss of receptor function
(Kuryatov et al., 1997; Figl et al., 1998; Bertrand et al., 2002). As of
mid-2002, five different missense mutations in the M2 regions of
the 42 nicotinic acetylcholine receptor (nAChR) are known
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that cause ADNFLE. Therefore we assessed the L9S mice for
sensitivity to nicotinic seizures, and we report a dramatic
hypersensitivity.
Materials and Methods
Mice. Generation of the L9S strain, by replacing the native4 subunit of
the nAChR with a mutated form, has been described previously (Labarca
et al., 2001). Male and female mice heterozygous for the L9S mutation
and their wild-type (WT) littermates were used for behavioral, in vivo
electrophysiological, neuroanatomical and neurochemical studies. Ex-
periments were performed according to National Institutes of Health
and local institutional guidelines for the humane treatment of laboratory
animals. Mice that appeared to be in extreme and/or prolonged pain were
killed.
Behavioral responses. Mice were placed in the behavior room 4 d before
experiments and were maintained on a 12 hr light/dark cycle with ad
libitum access to food and water. Acute behavioral responses to nicotine,
mecamylamine, epibatidine, bicuculline, galanthamine, tacrine, mor-
phine sulfate, and naloxone were determined in L9S and WT mice.
Unless specified, drugs and chemicals used in these studies were obtained
from Sigma (St. Louis, MO). Galanthamine and tacrine were purchased
from Tocris (Ellisville, MO). Drugs were dissolved in saline, and concen-
trations were adjusted so that total volume injected was 10 l/gm body
weight. Initial dose and mode of administration (subcutaneous versus
intraperitoneal) for each drug were based on reports in the literature.
Animals injected with the various compounds were placed inside a Plexi-
glas cage (30 14 cm), videotaped with a digital camcorder, and behav-
iorally scored by experimenters blind to their genotype. Mice were vid-
eotaped starting 1 min before and for 5–15 min after a single injection.
Frequency, duration, and time of onset of the behavioral responses (sei-
zure, Straub tail, sedation, circling, shaking) to each drug treatment were
recorded and tabulated. Seizure intensity assessment was based on a
recently developed scale (Franceschini et al., 2002).
In vivo electrophysiology. Simultaneous video-electroencephalo-
graphic recordings were obtained from free moving animals. Stereotaxic
surgeries were performed on mice anesthetized with a ketamine (100
mg/kg) and xylazine (25 mg/kg) mixture using mouse atlas coordinates
(Franklin and Paxinos, 1997). A pair of 0.1-mm-diameter tungsten wire
electrodes (200 k AC impedance) were inserted through a hole
drilled in the cranium and placed stereotactically within the hippocam-
pus (1.9 mm caudal to bregma, 1.4 mm lateral to midline, at a depth of
1.8 mm). A ground screw electrode was placed into the contralateral side
of the skull. A three pin connector (ground electrode plus two recording
electrodes) was cemented to the skull surface with dental acrylic. After
surgery, mice were allowed to recover for 48 hr. Electrophysiological
recordings started 10 min before and continued for 15 min after a single
nicotine injection of either 2 or 10 mg/kg. Data were acquired with a
differential amplifier (World Precision Instruments, Hamden, CT), us-
ing a sampling rate of 10 kHz and bandpass filtered (1–200 Hz). Data
analysis was performed with pClamp 8.2 software (Axon Instruments,
Union City, CA). Changes in EEG activity attributable to nicotine were
assessed by calculating SD and power spectra before and after nicotine
injection. Power spectrum analysis used a Hamming transform on 150
sec of continuous data.
Neuroanatomy. Brain sections obtained from three WT and three L9S
adult mice were Nissl-stained. For histology, animals were deeply anes-
thetized by carbon dioxide inhalation and then perfused with saline con-
taining 0.1% heparin, followed by 4% formaldehyde. Brains were dehy-
drated by successive ethanol washes (50, 70, and 96%), brought into a
mixture of diethyl ether and 100% ethanol (1:1), and embedded in cel-
loidin. Frontal series of 50-m-thick sections were cut on a sliding mic-
rotome (Reichert-Jung, Hamburg, Germany). Sections were stained in a
heated 0.1% aqueous solution of toluidine blue (Merck, Darmstadt, Ger-
many), washed in mild hydrochloric acid solution, and later transferred
to 96% ethanol. Finally, sections were mounted onto slides, dehydrated
with optal, bathed in xylene, and coverslipped with Canada balsam. Sec-
tions were examined with a Zeiss (Oberkochen, Germany) Axiophot
microscope and digitized with an AxioCam HRc digital camera.
Epibatidine binding. [ 125I]Epibatidine binding was used for quantitat-
ing nicotinic receptor levels (Marks et al., 1998). The particulate fraction
of brain homogenates was washed three times in hypotonic buffer at
12,000 g to obtain a purified membrane preparation. Incubations were
performed in 96 well plates in 30 l of binding buffer (in mM: 140 NaCl,
1.5 KCl, 2 CaCl2, 1 MgSO4, and 25 HEPES, pH 7.5) for 2 hr at 22°C using
200 pM [ 125I]Epibatidine. Cytisine was used to displace epibatidine
counts thought primarily to reflect 42 receptors. Incubations were
terminated by filtration into Gelman A/E glass fiber filters, followed by
washes with ice-cold buffer. Inhibition curves were fitted to either one or
two site models.
Synaptosomal studies. Thalamus taken from adult mice, which is a
nicotinic receptor-rich region, were used for synaptosome preparation.
After dissection, tissue was immediately placed in 10 vol of ice-cold iso-
tonic sucrose buffered solution (5 mM HEPES) and homogenized by
hand using a glass–Teflon tissue grinder. The supernatant was centri-
fuged at 12,000 g for 20 min, and the resulting pellet was resuspended
in an isotonic buffer to obtain fresh synaptosomes. For rubidium efflux
experiments, loading of synaptosomes was achieved by incubation with 4
Ci of carrier-free 86Rb at 22°C for 30 min in loading buffer (in mM: 140
NaCl, 1.5 KCl, 2 CaCl2, 1 MgSO4, 25 Na HEPES, 20 glucose, pH 7.5).
During the final 5 min of uptake, 10 mM diisopropyl fluorophosphate
was added to inhibit ACh esterase. After uptake, samples were filtered
under gentle vacuum and washed with 0.5 ml of loading buffer. Filters
containing synaptosomes were transferred to a polypropylene platform
and perfused with 135 mM NaCl, 5 mM CsCl, 1.5 mM KCl, 2 mM CaCl2, 1
mM MgSO4, 0.1% BSA, 50 nM TTX, 20 mM glucose, and 25 mM HEPES,
pH 7.5. Buffer was applied and removed with peristaltic pumps. The
effluent passes through a 200l Cerenkov cell within a counter (IN/US
Systems) that provides continuous online detection. Samples were stim-
ulated for 5 sec with ACh or nicotine by diverting buffer flow through a
200 l loop. Responses were normalized to the basal efflux rate, which
was fitted to a one or two component decay model.
Statistical analysis. Results were analyzed using Sigmastat, Origin, or
Excel. Differences among means were considered significant when they
were attributable to randomness with5% chance. For data with n 6,
we verified normal distribution and random error distribution of the
data.
Results
Behavioral responses in hypersensitive knock-in mice
L9S mice were more sensitive to several effects of nicotine than
their WT littermates (Fig. 1). The first example is nicotine-
induced seizures. A seizure consisted of clonic–tonic activity and
a loss of equilibrium, equivalent to four to five in the seizure scale
of Franceschini et al. (2002). For both WT and L9S mice, more
animals displayed seizures at increasing nicotine doses (Fig. 1A),
and the seizures began sooner after nicotine injection (Fig. 1B).
However, these dose–response relationships were dramatically
shifted to lower concentrations for the L9S mice. All L9S mice
injected with 2 mg/kg nicotine displayed seizures, whereas a con-
centration of 10 mg/kg was required to elicit seizures in 100% of
WT animals. In general, WT mice with seizures displayed a more
complex behavioral pattern than L9S mice, which included cir-
cling, free running, and jumping. The nicotinic receptor antago-
nist mecamylamine completely blocked seizures induced by nic-
otine (1.5 mg/kg) in all L9S animals tested (Fig. 1F).
Spande et al. (1992) described Straub tail (a nearly vertical tail)
as a response to nicotinic agonists in studies of epibatidine.
Straub tail is the most sensitive nicotine effect we have found in
L9S mice (Fig. 1C,D): 65% of L9S mice injected with a nicotine
concentration of 0.1 mg/kg displayed Straub tail, but none had
seizures (Fig. 1E). In L9S mice, seizures were always preceded by
Straub tail. In WT mice, in contrast, no nicotine concentration
was found to induce Straub tail only, but when Straub tail did
occur, it was always during seizure. Mecamylamine blocked nic-
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otine (1.5 mg/kg)-induced Straub tail in two of five L9S mice
tested and, in the remaining three animals, delayed the onset of
Straub tail by sixfold, compared with animals that received nico-
tine alone (Fig. 1F).
In addition to nicotine hypersensitivity, L9S mice were also
more sensitive than WT mice to epibatidine (Fig. 2A). Epibati-
dine induced seizures and Straub tail in L9S animals at concen-
trations (10 g/kg) that caused no noticeable effects in WT
animals. Epibatidine seizures in L9S animals were always pre-
ceded by Straub tail. For epibatidine, as for nicotine, Straub tail
was the more sensitive assay: at a dose of 2g/kg, most L9S mice
displayed Straub tail but none had seizures.
Although L9S mice were hypersensitive to nicotine and epi-
batidine, L9S and WT mice showed similar sensitivity to the
GABAA receptor blocker bicuculline (Fig. 2B). Bicuculline in-
duced seizures and Straub tail in both L9S and WT mice in a
dose-dependent manner. Both L9S and WT animals had very
severe, prolonged, and in some cases lethal bicuculline-induced
seizures.
We also studied Straub tail and seizure responses to galan-
thamine and tacrine, two drugs thought to operate on cholinergic
systems (Fig. 2C,D). L9S mice displayed Straub tail responses at
significantly lower concentrations than WT mice for both drugs.
In fact, there were no Straub tail responses in WT mice at any
concentration up to 160 mg/kg tacrine, the highest concentration
tested; but 50% of L9S mice responded with Straub at10 mg/
kg. L9S mice were also hypersensitive to galanthamine- or
tacrine-induced seizures; galanthamine induced seizures at ap-
proximately fourfold lower concentrations in the mutant than
Figure 1. Nicotine induction of seizures and Straub tail in L9S and WT littermate mice. A, B,
Animals received a single subcutaneous nicotine injection, and the percentage of mice that
showed seizures and the time of seizure onset were recorded. C, D, Animals used in A were also
scored for Straub tail. The percentage of mice responding and the time of Straub onset were
recorded. Continuous video recording of the mice after nicotine injection lasted 430 sec. Ani-
mals that did not respond during video recording time were assigned a 430 sec onset time. Each
data point from the onset graphs is the mean  SE; n  6. E, Comparison of percentage
responses for Straub tail and seizure in L9S mice, showing the higher sensitivity to Straub tail.
F, L9S animals received either a saline or a 2 mg/kg intraperitoneal mecamylamine injection,
followed by a 1.5 mg/kg subcutaneous nicotine injection 5 min later. Time to seizure and Straub
tail were recorded. Each bar represents mean SE; n 5. The horizontal line indicates the
maximum observation period (600 sec). None of the mecamylamine plus nicotine-treated mice
had seizures, and 60% displayed Straub tail during this period.
Figure 2. Epibatidine, bicuculline, galanthamine, or tacrine induction of seizures (left pan-
els) and Straub tail (right panels) in L9S and WT littermate mice. A, Animals received a single
subcutaneous epibatidine injection, and the times of seizure and/or Straub tail onset were
recorded. B, Animals received a single bicuculline intraperitoneal injection, and the times of
seizure and/or Straub tail onset were recorded. C, Animals received a single intraperitoneal
galanthamine injection, and the times of seizure and/or Straub tail onset were recorded. D,
Animals received a single subcutaneous tacrine injection, and the times of seizure and/or Straub
tail onset were recorded. Mice with seizures lasting5 min were killed. Animals injected with
epibatidine or bicuculline that did not respond during video-recording time were assigned a 350
sec onset time. Animals injected with galanthamine that did not respond were assigned a 450
sec onset time, and nonresponding mice treated with tacrine were assigned a 600 sec onset
time. Each data point is the mean SE; n 4 or 6. There was a significant difference in seizure
onset between WT and L9S mice injected with 40 or 80 mg/kg tacrine ( p 0.05).
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WT mice (Fig. 2C). Mice were less sensitive to tacrine effects than
to other drugs tested: tacrine induced seizures in WT mice only at
doses 80 mg/kg and only after 400 sec; and we noted that
tacrine-injected mice displayed seizures only after spontaneous
or handling-initiated movements. Nonetheless, the data show
that L9S mice were significantly more sensitive than WT mice to
tacrine when handled similarly ( p  0.05 at 40 and 80 mg/kg)
(Fig. 2C).
Straub tail is often measured as a response to opioids. Mor-
phine did induce Straub tail in L9S mutant mice (Fig. 3A). How-
ever, there were clear differences in the characteristics of Straub
tail induced by morphine and nicotine. Morphine-induced
Straub tail began, on average, 10 min after morphine injection, in
contrast to the delay of1 min after nicotine injection (Fig. 3B).
Furthermore, morphine-induced Straub tail, but not nicotine-
induced Straub tail, was completely blocked by the -opioid re-
ceptor antagonist naloxone.
In vivo electrophysiological recordings show hypersensitivity
to nicotine
Field recordings from hippocampi of L9S mice (n 6 animals)
revealed changes in the EEG trace after a seizure-inducing dose of
2 mg/kg nicotine (Fig. 4). Onset of behavioral seizure coincided
in time with an increase in amplitude of the EEG trace (Fig. 4B).
No consistent changes in EEG amplitude were observed in WT
mice (n 3) after 2 mg/kg nicotine injection, concentrations at
which these mice displayed no behavioral seizures (Fig. 4A).
Power spectra of the records in L9S mice showed a large
nicotine-induced increase in power density at theta frequencies
(7 Hz). Four of the six L9S mice displayed greater than or equal
to threefold enhancement of theta rhythm power after nicotine
injection (Fig. 4B). Also, the SD of the records increased mark-
edly in most L9S animals but not in WT animals (Fig. 4A). One
L9S animal displayed spike-wave hippocampal discharges.
We also recorded EEG traces in five WT mice after 10 mg/kg
nicotine injection, which led to seizures in each animal (Fig. 4C).
The signals in these WT nicotine-treated mice were much more
complex than the sustained and increased EEG amplitude in L9S
mice at 2 mg/kg. EEG traces of WT animals during seizure
showed bursts of activity (3– 6 sec). In most of these nicotine-
treated WT animals, there were increases in power over the spec-
trum from 1 to 20 Hz (Fig. 4C). Only one of these animals
showed an increase in theta rhythm alone; two animals showed
spike waves during seizures. During intervals between behavioral
seizures, there was little or no abnormal electrical activity.
Neuroanatomy
Various brain structures including the frontal cortex, hippocam-
pus, thalamus, and hindbrain were examined to determine
whether the L9S mutation caused gross anatomical abnormali-
ties. In Nissl-stained sections (Fig. 5), layering appeared normal
and all major cell groups were present.
Neurochemical studies: knock-in mice have fewer receptors,
but many are hypersensitive
In this section, we explicitly refer to adult L9S mice as L9S
heterozygotes. Figure 6A shows [ 125I]epibatidine binding in
adult mice thalamus preparations, and Figure 6B shows
[ 125I]epibatidine binding in fetal mice whole-brain preparations.
Epibatidine saturation curves in preparations of adult mice thal-
amus show a decrease in epibatidine binding from 98.8 fmol/mg
protein in WT mice to 64.1 fmol/mg protein in L9S heterozy-
gotes, with KD values of 64.1 pM and 69.8 pM, respectively. This
35% decrease in maximal binding, with indistinguishable KD val-
ues, is presumably attributable entirely to decreased expression
from the mutant allele, implying that the mutant allele has70%
less expression than the WT allele. The decreased expression is
thought to occur not because of the point mutation but because
of the 2 kb neomycin-resistance cassette in the intron down-
stream from exon 5 (Labarca et al., 2001). Decreased expression
because of the presence of the neomycin cassette has been re-
ported in other neo-intact mice (Wang et al., 1999; Single et al.,
2000; Broide et al., 2002). It has been suggested that the neomycin
cassette may interfere with splicing or other post-transcriptional
events that would result in decreased protein expression (Balfour,
1994). Greater precision and confirmation of reduced receptor
expression calls for measurements on homozygous L9S mice.
These mice die neonatally, preventing such experiments on
adults. We therefore performed [ 125I]epibatidine binding exper-
iments on fetal mouse brains (Fig. 6B), although only adults were
used for the behavioral, pharmacological, and electrophysiolog-
Figure 3. Morphine and nicotine induction of Straub tail in L9S mice. Animals received a
subcutaneous morphine or nicotine injection 10 min after an intraperitoneal naloxone or saline
injection. Morphine and nicotine induced Straub tail in L9S mice. A, Morphine Straub induction
was blocked by the-opioid receptor antagonist naloxone. *p0.01 when comparing saline-
and naloxone-treated groups (t test; n 4). B, Nicotine-induced Straub was unaffected by
naloxone. Experiments lasted 30 min, and animals not responding within that time received a
30 min onset score. Each bar represents mean SE; n 4.
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ical experiments reported in this paper. There is a gene dose-
dependent decrease in total epibatidine binding from 75.7
fmol/mg protein in WT mice to 51.3 fmol/mg protein in het-
erozygous L9S fetal mice and to 23.4 fmol/mg protein in fetal
mice homozygous for the mutation (and for the adjacent neo
cassette). The apparent KD values in fetal mice are unaffected by
the mutation (20.7, 21.8, and 19.6 pM, respectively). Because
equilibrium ligand-binding experiments with nicotinic receptors
are dominated by binding to desensitized state(s), the unchanged
affinity between WT and heterozygous L9S mice may indicate
that, although the open state occurs at a lower agonist concentra-
tion in the L9S mutations, there is little change in the affinity for
desensitized state(s). Cytisine-sensitive [ 125I]epibatidine binding
provides an accurate measurement of 4-containing receptors
4
with 2 mg/kg nicotine or WT mice injected with 10 mg/kg nicotine (n 5) compared with WT
mice (n 3) injected with 2 mg/kg nicotine (*p 0.05). There was no behavioral or electro-
encephalographic evidence of seizure in any wild-type mouse injected with nicotine (2 mg/kg).
Figure 4. Traces from hippocampal field recordings and power spectrum analysis in WT ( A)
and L9S ( B) mice, respectively, before and after a 2 mg/kg nicotine injection. Raw traces and
power spectra analysis reveal an increase in peak-to-peak signal and theta rhythm amplitude,
respectively, during seizure in the L9S animal. C, A typical WT mouse, before and 10 min after
a 10 mg/kg nicotine injection. Each power spectrum represents 1 min of continuous data. D,
Box-plot graph showing a significant increase in the SD of L9S traces (n 6 animals) injected
Figure 5. Nissl-stained coronal brain sections of WT (left panels) and L9S (right panels)
mice. A, Frontal cortex shown at the level of the primary motor cortex. Layers are labeled. B,
Ventrolateral aspect of the thalamus. VL, Nucleus ventralis lateralis thalami; VP, nucleus vent-
ralis posterior thalami; RT, nucleus reticularis. C, Hippocampus and adjacent secondary visual
cortex. D, Dorsomedial aspect of the hindbrain, including area postrema (AP) and the hypoglos-
sal nucleus (12).
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(Marks et al., 1998, 2000). Figure 6C shows cytisine-sensitive
high-affinity epibatidine binding in fetal mice. The primary effect
of the 4 L9S mutation is a gene dose-dependent, significant
reduction of the cytisine-sensitive component, from 47.7 to 29.1
to 12.3 fmol/mg, with little effect on cytisine affinity (F(2.9) 
246.19; p  10	4). These data allow the conclusion that the
neomycin-selection cassette reduces the expression of the mu-
tated 4 subunit by 75% in fetal mice, similar to the value
(70%) calculated from the less precise experiments in heterozy-
gote L9S adults.
There is a small, insignificant decrease in the cytisine-resistant
component between the WT to the L9S homozygote (Fig. 6D).
Low-affinity epibatidine binding sites displaced by cytisine were
12.9 fmol/mg in WT and 16.7 fmol/mg in heterozygote L9S
mice, several fold lower than the value for high-affinity epibati-
dine binding sites in WT mice.
We measured agonist-stimulated 86Rb efflux in adult fore-
brain synaptosomes as a functional complement to the epibati-
dine binding (Fig. 7). Synaptosomes stimulated by increasing
concentrations of acetylcholine (Fig. 7A) or nicotine (Fig. 7B)
released increasing amounts of 86Rb. At higher agonist concen-
trations, synaptosomes obtained from L9S mice had nearly two-
fold less rubidium efflux than WT mice after stimulation by ei-
ther acetylcholine or nicotine, presumably because the mutant
mice had fewer receptors. However, these differences were
smaller at low concentrations. The 86Rb efflux data were analyzed
in terms of two saturable components. The high-affinity compo-
nent (maximal flux, V1) accounted for a threefold to fourfold
higher fraction of the efflux for the mutant mice than for WT
mice. It should be understood that such an analysis is formal and
cannot be readily related to agonist–receptor interactions on a
millisecond time scale. Nonetheless, this analysis reveals that the
mutant mice have a gain of function at low ACh and nicotine
concentrations, consistent with previous data from heterologous
expression of the mutant receptor (Labarca et al., 2001) and with
the behavioral and electrophysiological data presented above.
We also measured GABA release from the hippocampus of
L9S and WT mice (S. McCallum, M. J. Marks, and A. Collins,
unpublished observations). The results showed no significant
difference (10%) between the KCl- and ACh-stimulated GABA
efflux between the two genotypes, suggesting that there are no
differences in the proportion of GABAergic nerve terminals. The
measurements of ACh-stimulated release lack the precision of the
Rb release experiments but show no significant difference
(20%) between Vmax for the two genotypes. The EC50 for re-
lease (1–3 M), also showed no significant differences between
the two genotypes.
Discussion
Molecular, cellular, and circuit basis of the seizure phenotype
Our results show that, when the WT 4 nAChR subunit is re-
placed by the L9S mutant, mice become dramatically (approxi-
mately eightfold) more sensitive to nicotine-induced seizures. An
analogous hypersensitive nAChR knock-in mouse line, the 7
L9T strain, shows a twofold increase in seizure sensitivity
(Broide et al., 2002). The difference in seizure threshold between
4 and7 mutant mice may be attributable in part to the fact that
42 receptors have much lower EC50 values (100-fold) for
nicotine than homomeric 7 receptors. The nicotine-induced
seizures in WT mice were more complex than those induced by
lower nicotine levels in L9S mice, as assessed by both behavioral
criteria and by in vivo electrophysiology (Fig. 4), in keeping with
the idea that WT nicotine-induced seizures arise from actions on
additional nAChRs, probably including 7. The remote possibil-
ity that the 38% decrease in 4 subunits leads to unexpected
compensatory changes at other nicotinic receptors, and in turn to
the increased seizure sensitivity, is rendered unlikely by the fact
Figure 6. [ 125I]Epibatidine binding to mouse brain membranes. A, Epibatidine binding in
membranes prepared from adult WT and heterozygous (Het) L9S brains. Each data point is the
mean SE; n4. B, Epibatidine binding in membranes obtained from WT, heterozygous, and
homozygous (Hom) embryonic brains. Each data point is the mean SE; n 4. C, D, Cytisine-
sensitive and cytisine-resistant epibatidine binding, respectively, in embryonic membranes.
Each data point is the mean SE; n 4; *p 0.01.
Figure 7. Rubidium efflux from synaptosomes prepared from adult WT () and heterozy-
gous L9S (F) mouse brains. In each case, the curves represent fits to two components of efflux.
The EC50 values (K1, K2) and maximal efflux (V1, V2) are given in the boxes. A, Acetylcholine
induced rubidium efflux. Each data point is the mean SE; n 5. B, Nicotine (Nic)-induced
rubidium efflux. Each data point is the mean SE; n 5. Het, Heterozygous.
Fonck et al. • Agonist-Induced Seizures in4-nAChR L9S Mice J. Neurosci., April 1, 2003 • 23(7):2582–2590 • 2587
(1) that changes in nicotine-induced seizures have not been re-
ported for 4 knock-out mice, and (2) that 4 knock-out mice
have an apparent increased sensitivity to bicuculline-induced sei-
zures, in contrast to the present strain (Wong et al., 2002).
The L9S mutation is not an identified ADNFLE mutation,
but it is nonetheless informative. One ADNFLE mutation is at 10
and involves a Leu to Ser switch. The periodicity of mutational
effects in the M2 region (Devillers-Thiery et al., 1992) is consis-
tent with the hypothesis that an L9S mutation could have phys-
iological effects like an S10L mutation, and several studies indi-
cate that the S10L mutation has a gain-of-function character
(Figl et al., 1998; Bertrand et al., 2002). We therefore propose that
knock-in mouse strains bearing the ADNFLE mutations would,
like the present strain, have increased susceptibility to seizures. If
this hypothesis is verified, the proposed knock-in strains would
serve as models for ADNFLE. We lack the equipment to observe
these mice systematically for the presence of spontaneous seizures,
but in the course of handling several hundreds of these mice for 4
years, including 24 hr ambulation and activity monitoring, we
have observed non-agonist-induced seizures only in tacrine-
injected mice, which developed handling-induced seizures.
How do gain-of-function 4 nAChRs render a mouse hyper-
sensitive to nicotine-induced seizures? CNS nAChRs may act pri-
marily to modulate presynaptic neurotransmitter release, rather
than to produce postsynaptic EPSCs (for review, see Wonnacott
et al., 1990; Wonnacott, 1997; but see Ji et al., 2001). After stim-
ulation by a nicotinic agonist, presynaptic nAChR responses
could cause terminal depolarization, which in turn would facili-
tate either excitatory or inhibitory neurotransmitter release.
There is good evidence that 4 receptors are primarily on
GABAergic interneurons in the hippocampus and neocortex
(Alkondon et al., 1997). Therefore activation of inhibitory termi-
nals may result in enhanced GABA release, which, depending on
the affected circuit, could inhibit primarily inhibitory pathways,
resulting in net excitation. In another scenario, activation of in-
hibitory terminals and consequent GABA release could contrib-
ute to seizure induction by synchronization of glutamatergic
neuronal activity (Mody, 1998). Measurements to date indicate
only a relatively modest change in ACh-stimulated hippocampal
GABA release in the L9S mutants, suggesting that these changes
may occur in only a subset of GABAergic interneurons.
In confirmation of these ideas, relatively low nicotine doses in
awake L9S animals did produce changes in field recordings ob-
tained from chronically implanted electrodes. There was an in-
crease in the peak-to-peak amplitude of EEG traces during be-
havioral seizures, primarily because of an increased theta rhythm.
This observation is consistent with models of extracellular theta
current generation in the cortex (Buzsaki, 2002). Cholinergic
neurons in the medial septum projecting to pyramidal cells in the
hippocampus provide “pacemaker” theta activity in the brain via
both muscarinic and nicotinic pathways (Petsche et al., 1966). In
our experiments, the presence of hypersensitive 4 nAChRs,
stimulated by nicotine, apparently results both in seizure activity
and in an enhanced hippocampal theta rhythm, presumably in-
volving the septohippocampal pathway. Because we did not con-
sistently observe spike-wave activity in the hippocampal record-
ings from the L9S mice, our data do not allow the conclusion
that the seizures originated in the hippocampus.
Hypersensitivity to several nicotinic agonists but not to
other drugs
Several compounds were tested to determine the specificity of the
L9S mutation effects on seizure and Straub tail. First, nicotine-
induced seizures in L9S mice were completely blocked by the
nicotinic antagonist mecamylamine. Second, epibatidine, a nic-
otinic receptor agonist (Badio and Daly, 1994), caused Straub tail
and seizure in L9S mice at much lower concentrations than in
WT mice. In contrast, bicuculline, a GABAA receptor blocker and
commonly used proconvulsant, caused Straub tail and seizure at
similar concentrations in L9S and WT mice, suggesting that the
mutation did not yield a generalized seizure phenotype. There-
fore it is unlikely that hypersensitive 4 nAChRs are chronically
activated, with a consequent tonic release of excitatory neuro-
transmitter, and thus maintaining a lowered seizure threshold.
Specificity of the Straub tail response observed in L9S mice was
examined with morphine. Morphine-induced Straub tail onset
was 10 times longer than nicotine-induced Straub tail onset,
and it was completely blocked by the -opioid receptor blocker
naloxone. Nicotine-induced Straub tail was significantly dimin-
ished by mecamylamine but unaffected by naloxone. Hence, in
L9S mice, Straub tail induction by morphine was very different
from that obtained with nicotine. In sum, the behavioral effects
observed in L9S mice appear specific to the stimulation of 4-
containing nicotinic circuits.
Tacrine and galanthamine are widely used to delay the cogni-
tive decline associated with Alzheimer’s disease and other de-
mentias. Both of these drugs produced seizure and Straub effects
at lower concentrations in L9S mice than in WT mice (Fig.
2C,D), consistent with the view that, by blocking cholinesterase,
these drugs produce elevated ACh concentrations near ACh re-
ceptors. There is a approximately a fourfold range of galan-
thamine and tacrine concentrations in which these elevated ACh
concentrations appear detectable by hypersensitive but not by
normal receptors. Originally it was thought that both drugs were
cholinesterase inhibitors and therefore counteracted the effects of
cholinergic neuron death. Recent papers propose, however, that
galanthamine, but not tacrine, is also a direct allosteric modula-
tor of the42 receptor (Samochocki et al., 2000; Maelicke et al.,
2001). If so, one would expect a mouse with hypersensitive 42
receptors to show a dramatically enhanced behavioral effect of
galanthamine compared with tacrine. The L9S mice are indeed
somewhat more sensitive to galanthamine than to tacrine (Fig.
2C,D), providing some evidence for the hypothesis (Fig. 2C,D).
There are wide variations in the previously described effective
doses for cognitive effects of tacrine and galanthamine in WT
mice; the effective doses in the present study seem higher than the
range for both drugs (Vincent et al., 1988; Sweeney et al., 1989;
Pavone et al., 1998).
Gene dosage effects on viability and hypersensitivity of
L9S strains
We originally designed the L9S strain to provide a severe gain of
function (Labarca et al., 2001); unexpectedly, when both 4 sub-
units are mutant, the 4(L9S)2 receptor becomes so sensitive
that it actually opens partially in response to choline at concen-
trations that are present in the CSF (Labarca et al., 2001). In both
the neo-deleted heterozygote and the neo-intact homozygote
(but not in the neo-intact heterozygote studied here), the result-
ing excitotoxic damage apparently kills many dopaminergic neu-
rons, and the former two genotypes die soon after birth (Labarca
et al., 2001).
The present study shows that the neo-intact allele is expressed
at 25% of WT levels (Fig. 6). The decrease in high-affinity
epibatidine binding occurs in the cytisine-sensitive but not in the
cytisine-resistant fraction, thus indicating that changes in expres-
sion correspond primarily to42 receptors rather than to other
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nicotinic receptors such as 7, 32, 34, or 623. The fact
that there were no significant changes in epibatidine binding of
the cytisine-resistant fraction also suggests that no major com-
pensatory mechanisms at the level of nicotinic receptor expres-
sion took place.
Figure 8 presents our view of the relationships among gene
dosage, receptor composition, and viability. In brief, only 20% of
the 4 subunits are hypersensitive, and the total number of 4
subunits is only63% of normal levels. These values lead to the
conclusion that only4% of the receptors have two 4L9S (de-
noted 4* in Fig. 8) subunits, which are activated by choline.
Presumably this small number of choline-activated subunits is
consistent with viability. These receptors are also 30-fold more
sensitive than normal to either ACh or nicotine (Labarca et al.,
2001). Some 32% of the receptors have one 4L9S subunit and
one WT subunit; previous data on the muscle nAChR suggest
that these receptors have an intermediate level of hypersensitivity
(Labarca et al., 1995), although this point has not been measured
systematically. We do not know whether the profound agonist-
sensitive phenotypes of the present heterozygote L9S mouse
arise primarily from the 4% of receptors with extreme hyper-
sensitivity or from the 32% with moderate hypersensitivity.
Experiments with less drastically hypersensitive and more viable
4 receptor knock-in strains are now under way and may settle
this point.
Incidentally, the neonatal lethality of the homozygous L9S
line is in contrast to the viability of the 4 knock-out mice (Ma-
rubio et al., 1999; Ross et al., 2000). This fact provides additional
evidence that the presence of the hypersensitive mutated receptor
rather than a decrease in receptor expression, which is complete
in the case of the 4 knock-out, is responsible for the observed
lethality.
Conclusions
These studies emphasize the utility of gain of function L9S
knock-in mice for examining the function of 4-containing
nAChRs in the brain. Data to be reported elsewhere on these mice
show the importance of the 4 subunit in mediating nicotine
analgesia in supraspinal responses and the minimal 4 modula-
tion of nociception in spinal reflex pathways. The increased sen-
sitivity to agonist-induced seizures of the4 L9S subunit may be
relevant to the pathophysiology of ADNFLE caused by various
mutations in the M2 domain of 4 and 2 receptor subunits.
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